162 related articles for article (PubMed ID: 15470269)
1. Oxidative stress in NRTI-induced toxicity: evidence from clinical experience and experiments in vitro and in vivo.
Day BJ; Lewis W
Cardiovasc Toxicol; 2004; 4(3):207-16. PubMed ID: 15470269
[TBL] [Abstract][Full Text] [Related]
2. A brief overview of mechanisms of mitochondrial toxicity from NRTIs.
Kohler JJ; Lewis W
Environ Mol Mutagen; 2007; 48(3-4):166-72. PubMed ID: 16758472
[TBL] [Abstract][Full Text] [Related]
3. Nucleoside reverse transcriptase inhibitors induced hepatocellular mitochondrial DNA lesions and compensatory enhancement of mitochondrial function and DNA repair.
Liang Q; Zeng J; Wu J; Qiao L; Chen Q; Chen D; Zhang Y
Int J Antimicrob Agents; 2018 Mar; 51(3):385-392. PubMed ID: 28843815
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions.
Lewis W
Antiviral Res; 2003 May; 58(3):189-97. PubMed ID: 12767466
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial DNA replication, nucleoside reverse-transcriptase inhibitors, and AIDS cardiomyopathy.
Lewis W
Prog Cardiovasc Dis; 2003; 45(4):305-18. PubMed ID: 12638094
[TBL] [Abstract][Full Text] [Related]
6. HIV and mitochondrial toxicity in children.
Foster C; Lyall H
J Antimicrob Chemother; 2008 Jan; 61(1):8-12. PubMed ID: 17999978
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial defects arise from nucleoside/nucleotide reverse transcriptase inhibitors in neurons: Potential contribution to HIV-associated neurocognitive disorders.
Hung KM; Chen PC; Hsieh HC; Calkins MJ
Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):406-413. PubMed ID: 27840304
[TBL] [Abstract][Full Text] [Related]
8. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.
Anderson PL; Kakuda TN; Lichtenstein KA
Clin Infect Dis; 2004 Mar; 38(5):743-53. PubMed ID: 14986261
[TBL] [Abstract][Full Text] [Related]
9. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy.
Haugaard SB; Andersen O; Pedersen SB; Dela F; Richelsen B; Nielsen JO; Madsbad S; Iversen J
J Med Virol; 2005 Sep; 77(1):29-38. PubMed ID: 16032748
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.
Nolan D; Hammond E; Martin A; Taylor L; Herrmann S; McKinnon E; Metcalf C; Latham B; Mallal S
AIDS; 2003 Jun; 17(9):1329-38. PubMed ID: 12799554
[TBL] [Abstract][Full Text] [Related]
12. Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy.
Côté HC
Antivir Ther; 2005; 10 Suppl 2():M3-11. PubMed ID: 16152702
[TBL] [Abstract][Full Text] [Related]
13. Endothelial mitochondrial senescence accelerates cardiovascular disease in antiretroviral-receiving HIV patients.
Chen YF; Dugas TR
Toxicol Lett; 2019 Dec; 317():13-23. PubMed ID: 31562912
[TBL] [Abstract][Full Text] [Related]
14. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA.
Koczor CA; Lewis W
Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1493-504. PubMed ID: 20929279
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors.
Martin AM; Hammond E; Nolan D; Pace C; Den Boer M; Taylor L; Moore H; Martinez OP; Christiansen FT; Mallal S
Am J Hum Genet; 2003 Mar; 72(3):549-60. PubMed ID: 12587093
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial toxicity of nucleoside analogues: mechanism, monitoring and management.
Cherry CL; Lala L; Wesselingh SL
Sex Health; 2005; 2(1):1-11. PubMed ID: 16334706
[TBL] [Abstract][Full Text] [Related]
17. Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.
Orkin C; Llibre JM; Gallien S; Antinori A; Behrens G; Carr A
HIV Med; 2018 Jan; 19(1):18-32. PubMed ID: 28737291
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine.
Velsor LW; Kovacevic M; Goldstein M; Leitner HM; Lewis W; Day BJ
Toxicol Appl Pharmacol; 2004 Aug; 199(1):10-9. PubMed ID: 15289086
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy.
Lewis W
Antivir Ther; 2005; 10 Suppl 2():M13-27. PubMed ID: 16152703
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis.
Lewis W; Kohler JJ; Hosseini SH; Haase CP; Copeland WC; Bienstock RJ; Ludaway T; McNaught J; Russ R; Stuart T; Santoianni R
AIDS; 2006 Mar; 20(5):675-84. PubMed ID: 16514297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
